Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
Clinical trial NCT02163577 · COMPLETED
Trial details
- NCT number
- NCT02163577
- Sponsor
- Kyowa Kirin, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-02
- Primary completion
- 2018-10-30
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.